Nanocurcumin, a nanoparticle form of turmeric's active compound, was designed to fix curcumin's notoriously poor absorption. A new systematic review of 32 randomized trials finds it can lower inflammatory markers like CRP, IL-6, and TNF-α, most often at around 80 mg per day. But the benefit appears tied to disease: healthy people generally saw no significant change, while those with conditions such as NAFLD, kidney disease, and autoimmune disorders did more often. The authors also warn of heavy variation in formulations, doses, and trial lengths, so the results are promising but far from definitive.
This page is available in